CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
05/04/2023
Back to search
Official data from USPTO
MEDICAGO
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
45
Latest update
05/04/2023
Trademark type
Combined
Nice classes
5, 35, 40, 42
Filing date
08/03/2018
Registration date
10/26/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/26/2021
Last transaction
05/04/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
5
Owner type
03
Owner location
Québec (Québec), CA
Examiner
MESSICK, TABITHA
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the word "MEDICAGO" all in blue letters.
Holders and representatives
Holders
Medicago Inc.
Representatives
Michelle P. Ciotola CANTOR COLBURN LLP
Technical classification
Nice Classes
Class 5Class 35Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and medicinal preparations and substanceshuman vaccinestherapeutic proteins and antibodies for the treatment of infectious diseaseschronic diseases and cancer
Class 35
Wholesale store services featuring pharmaceuticalspharmaceutical ingredientsvaccinestherapeutic proteins and antibodiesexcluding healthcare plans and healthcare plan management/administration services
Class 40
Manufacture of pharmaceuticalspharmaceutical ingredientsvaccinestherapeutic proteins and antibodies for others; Custom manufacturing of pharmaceuticalspharmaceutical ingredientsvaccinestherapeutic proteins and antibodies
Class 42
Research and development in the field of vaccinesrecombinant proteins and antibodies for therapeutic and prophylactic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccinestherapeutic proteins and antibodies; product research and development and scientific researchall in the field of protein production using recombinant technologies through transient expression in plants; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticalspharmaceutical ingredientsvaccinestherapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates
Publications
History of USPTO decisions and trademark events.
45 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/04/2023
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
05/04/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/04/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/04/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
05/04/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
10/26/2021
CHPB
POST PUBLICATION AMENDMENT - ENTERED
09/21/2021
APET
ASSIGNED TO PETITION STAFF
09/16/2021
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
09/09/2021
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
09/07/2021
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
03/23/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/02/2021
PUBO
PUBLISHED FOR OPPOSITION
03/02/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/10/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/26/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/25/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/25/2021
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
01/22/2021
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
09/15/2020
GNSI
INQUIRY TO SUSPENSION E-MAILED
09/15/2020
CNSI
SUSPENSION INQUIRY WRITTEN
09/15/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
03/15/2020
GNSL
LETTER OF SUSPENSION E-MAILED
03/15/2020
CNSL
SUSPENSION LETTER WRITTEN
03/15/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/13/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/13/2020
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
03/12/2020
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
09/19/2019
GNSI
INQUIRY TO SUSPENSION E-MAILED
09/19/2019
CNSI
SUSPENSION INQUIRY WRITTEN
09/19/2019
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
09/09/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
03/06/2019
GNSL
LETTER OF SUSPENSION E-MAILED
03/06/2019
CNSL
SUSPENSION LETTER WRITTEN
03/06/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/02/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/02/2019
ALIE
ASSIGNED TO LIE
03/02/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/26/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/01/2018
GNRT
NON-FINAL ACTION E-MAILED
09/01/2018
CNRT
NON-FINAL ACTION WRITTEN
09/01/2018
DOCK
ASSIGNED TO EXAMINER
08/30/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/09/2018
NWAP
NEW APPLICATION ENTERED
08/07/2018
Continuous trademark protection
Get notified about every new filing that threatens MEDICAGO or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.